

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



**EXPECTED INCREASE IN PROFIT FOR
SHANGHAI MICROPORT ENDOVASCULAR MEDTECH (GROUP) CO., LTD.
FOR THE YEAR ENDED 31 DECEMBER 2021**

The board of directors (the “**Board**”) of MicroPort Scientific Corporation (the “**Company**”, together with its subsidiaries (the “**Group**”)) wishes to inform shareholders of the Company and potential investors that, based on the information currently available to the management, Shanghai MicroPort Endovascular MedTech (Group) Co., Ltd. (“**EV MedTech**”) is expected to record an increase in its profit for the year ended 31 December 2021.

EV MedTech is owned as to 46.34% by the Company and its results are consolidated with the financial statements of the Company. The shares of EV MedTech are listed on the science and technology innovation board of the Shanghai Stock Exchange.

The net profit attributable to the equity owners of EV MedTech for the year ended 31 December 2021 is expected to be between RMB300.46 million and RMB321.92 million, representing an increase of between 40% and 50% as compared with 2020. The net profit attributable to equity owners of EV MedTech after deducting extraordinary gains or losses is expected to be between RMB276.85 million and RMB295.94 million, representing an increase of between 45% and 55% as compared with 2020.

The main reason for the increase in profit was that in 2021, although there had been a recurrence of the COVID-19 epidemic, which to a certain degree impacted on the carrying out of surgical operations, the innovative products of EV MedTech, including Castor[®] Branched Aortic Stent-Graft System, Minos[®] Abdominal Aortic Stent-Graft and Delivery System and Reewarm[®] PTX Drug Coated Balloon PTA Catheter have all continued rapid growth in 2021. These products have further consolidated and enhanced the competitiveness of EV MedTech in the aortic and peripheral interventional market. At the same time, with the continuous expansion of EV MedTech’s innovative products in the international market, revenue from the overseas business has also achieved rapid growth.

Shareholders and investors are reminded that the financial information of EV MedTech above was prepared in accordance with PRC accounting standards and are limited solely to the operation of EV MedTech and are unrelated to the other subsidiaries of the Group. Such information is unaudited and has not been reviewed by the auditors or the audit committee of the Company, and does not (a) exclude intra-group transactions, (b) include all the business of the Group, and (c) represent or provide a full picture of the operation or status of the Group. **Shareholders and potential investors of the Company are reminded to exercise caution when dealing in the securities of the Company.**

By order of the Board
MicroPort Scientific Corporation
Dr. Zhaohua Chang
Chairman

Shanghai, the PRC, 25 January 2022

As at the date of this announcement, the executive Director is Dr. Zhaohua Chang; the non-executive Directors are Mr. Norihiro Ashida, Dr. Yasuhisa Kurogi and Mr. Hongliang Yu; and the independent non-executive Directors are Mr. Jonathan H. Chou, Dr. Guoen Liu and Mr. Chunyang Shao.

* *For identification purpose only*